	US 12,466,792 B2
	Compounds for the treatment of SARS
Arun K. Ghosh, West Lafayette, IN (US); Monika Yadav, West Lafayette, IN (US); and Andrew Mesecar, West Lafayette, IN (US)
Assigned to Purdue Research Foundation, West Lafayette, IN (US)
Filed by Purdue Research Foundation, West Lafayette, IN (US)
Filed on Oct. 23, 2023, as Appl. No. 18/492,411.
Application 18/492,411 is a continuation of application No. 17/826,061, filed on May 26, 2022, granted, now 11,834,408.
Claims priority of provisional application 63/194,638, filed on May 28, 2021.
Prior Publication US 2024/0124395 A1, Apr. 18, 2024
Int. Cl. C07D 207/26 (2006.01); C07D 227/087 (2006.01)

CPC C07D 207/26 (2013.01) [C07D 227/087 (2013.01)]

13 Claims

1. A compound of the formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R¹—O-1 to 4 carbon alkylene-6 to 10 membered aryl 6 to 10-membered heterocyclyl with one heteroatom or —O-1 to 4 carbon alkylene-6 to 10-membered heterocyclyl with one heteroatom, wherein the 6 to 10-membered heterocyclyl with one heteroatom is connected via a carbon atom on the 6 to 10-membered heterocyclyl group;

R²is alkyl, aryl, substituted aryl;

R³is 5-or 6-membered heterocyclyl with one to four heteroatoms, wherein the 5- or 6-membered heterocyclyl with one to four heteroatoms is connected to the —CH₂- group via a carbon atom on the 5- or 6-membered heterocyclyl group with one to four heteroatoms;

R⁴is H, alkyl or alkenyl; and

R^ais H or alkyl,

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 1 and at least one pharmaceutically acceptable excipient.